Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFECTS OF THROMBOXANE SYNTHASE INHIBITION ON IN-VIVO RELEASE OF INFLAMMATORY MEDIATORS IN CHRONIC ULCERATIVE-COLITIS
Autore:
CASELLAS F; PAPO M; GUARNER F; ANTOLIN M; SEGURA RM; ARMENGOL JR; MALAGELADA JR;
Indirizzi:
HOSP GEN VALLE HEBRON,DIGEST SYST RES UNIT,PSO VALL HEBRON SN E-08035BARCELONA SPAIN
Titolo Testata:
European journal of gastroenterology & hepatology
fascicolo: 3, volume: 7, anno: 1995,
pagine: 221 - 226
SICI:
0954-691X(1995)7:3<221:EOTSIO>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Keywords:
THROMBOXANE SYNTHETASE INHIBITION; COLONIC EICOSANOIDS; ELASTASE; CHRONIC ULCERATIVE COLITIS; COLONIC PERFUSION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
NO
Recensione:
Indirizzi per estratti:
Citazione:
F. Casellas et al., "EFFECTS OF THROMBOXANE SYNTHASE INHIBITION ON IN-VIVO RELEASE OF INFLAMMATORY MEDIATORS IN CHRONIC ULCERATIVE-COLITIS", European journal of gastroenterology & hepatology, 7(3), 1995, pp. 221-226

Abstract

Objective: To evaluate the effects of a thromboxane inhibitor on the production of eicosanoids by the colonic mucosa of patients with chronic ulcerative colitis. Patients and methods: Fourteen patients with active left-sided ulcerative colitis were divided into in two treatment groups. Seven patients received oral ridogrel (300 mg twice daily) andseven 5-aminosalicylic acid (5-ASA; 1 g twice daily) for 4 weeks. Intracolonic eicosanoid and elastase release were measured using a colonic double-lumen perfusion technique. An isotonic solution was infused 50 cm from the anal verge at the rate of 5 ml/min, and recovered by siphonage 30 cm distally. Effluents were assayed for thromboxane B2 (TXB2), prostaglandin E2 (PGE2), and leukotriene B4 (LTB4) by radioimmunoassay (RIA), and for polymorphonuclear elastase by immunoactivation. Clinical and colonoscopic criteria were used to determine activity beforeand after treatment. Results: Four of the seven patients in the ridogrel group and five of the seven in the 5-ASA group showed clinical andcolonoscopic improvement. Intraluminal elastase release decreased in every responding patient in the 5-ASA group (P < 0.05) and in three out of seven responders in the ridogrel group. Basal eicosanoid release was similar in both groups. In the responders, 5-ASA significantly reduced the release of the three eicosanoids (P < 0.05). Ridogrel reducedthe release of TXB2 to 31% of basal levels (P < 0.01) but the releaseof PGE2 and LTB4 was not affected. Conclusions: These results suggestthat ridogrel is an oral active selective inhibitor of thromboxane synthetase, which modifies the pattern of colonic eicosanoid generation in patients with chronic ulcerative colitis. Oral ridogrel may be a useful treatment for patients with non-severe ulcerative colitis, although specific indications require further studies.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/11/20 alle ore 21:08:38